Physician profile
Richard E Wells
NPI 1285865162
$6,957.86
in general payments reported to CMS, 2019-2025
32 companies · $470 in 2025
The $470 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $207 · 2021: $974 · 2022: $1,778 · 2023: $1,628 · 2024: $919 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,936 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,936.47 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $1,834.71 | 2019-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $721.60 | 2019-2025 | Ofev |
| Glaxosmithkline, LLC. | $692.31 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $511.52 | 2019-2024 | Fasenra, Breztri |
| Pfizer INC. | $499.25 | 2019-2024 | |
| United Therapeutics Corporation | $441.76 | 2019-2025 | Tyvaso, Tyvaso |
| Bayer Healthcare Pharmaceuticals INC. | $334.69 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $305.39 | 2021-2024 | Dupixent |
| Abbvie INC. | $249.27 | 2022-2025 | Avycaz, Teflaro |
| Mallinckrodt Hospital Products INC. | $242.59 | 2020-2023 | Acthar |
| Genzyme Corporation | $186.40 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $141.89 | 2022-2024 | Zerbaxa, Winrevair |
| Inari Medical, INC. | $93.23 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $73.13 | 2022-2023 | Glassia |
| Pulmonx Corporation | $72.04 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $71.32 | 2020-2024 | Xarelto |
| Insmed, INC. | $58.88 | 2022-2024 | Arikayce |
| Astellas Pharma US INC | $58.13 | 2019-2021 | |
| Genentech USA, INC. | $57.22 | 2019-2021 | |
| Vapotherm INC | $47.88 | 2020-2022 | |
| Gilead Sciences, INC. | $45.19 | 2019 | |
| Ambu INC. | $33.22 | 2025 | |
| Novartis Pharmaceuticals Corporation | $29.23 | 2019-2020 | |
| Mauna Kea Technologies, INC. | $26.63 | 2024 | |
| Mallinckrodt Enterprises LLC | $20.67 | 2019 | |
| Philips North America LLC | $20.65 | 2019 | |
| Ani Pharmaceuticals, INC. | $18.09 | 2024 | Purified Cortrophin Gel |
| Portola Pharmaceuticals, LLC | $17.52 | 2019 | |
| Mylan Specialty L.P. | $14.62 | 2019 | |
| Avanos Medical | $14.14 | 2021 | |
| La Jolla Pharmaceutical Company | $12.60 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $12.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.